Evaluation Of PF-00572778 And Alprazolam On Naloxone Challenge In Healthy Subjects
Status:
Terminated
Trial end date:
2008-02-01
Target enrollment:
Participant gender:
Summary
PF-00572778, a CRH antagonist, is expected to attenuate adrenocorticotropin (ACTH) and
cortisol responses to naloxone by blocking the effect of the CRH increases induced by
naloxone at the postsynaptic receptors. Demonstration of a statistically significant
attenuation of naloxone induced increases in cortisol and/or ACTH concentrations by
PF-00572778 compared to placebo would thus constitute proof of mechanism for the compound.
Therefore, this study is to evaluate pharmacodynamic effects of PF-00572778 following
naloxone challenge in healthy subjects.